Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lyell Immunopharma, Inc. - Common Stock
(NQ:
LYEL
)
14.86
-0.14 (-0.93%)
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lyell Immunopharma, Inc. - Common Stock
< Previous
1
2
3
Next >
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
November 04, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
November 04, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
November 04, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma To Participate in November Investor Events
November 02, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
September 14, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
September 10, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
August 06, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 25, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
June 12, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
June 08, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
June 04, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 01, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in May Investor Conferences
May 12, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
May 06, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
April 07, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
March 12, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
March 09, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in March Investor Conferences
February 23, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
February 12, 2026
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
December 24, 2025
Issued on behalf of GT Biopharma, Inc.
From
Equity Insider
Via
GlobeNewswire
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
December 07, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
November 12, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
November 10, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
November 03, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
September 03, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Participation in September Investor Conferences
September 02, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
August 12, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
July 25, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
June 23, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
June 17, 2025
From
Lyell Immunopharma, Inc
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
